Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ).
ImmuneOnco Biopharmaceuticals has received approval from the Center for Drug Evaluation of the National Medical Products Administration for its Phase III clinical study protocol of IMM0306, a bispecific molecule for treating relapsed/refractory follicular lymphoma. This approval marks a significant step in advancing their innovative treatment, potentially enhancing therapeutic outcomes by effectively eliminating malignant B cells while minimizing toxicity.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on the development of innovative cancer treatments. The company specializes in creating bispecific molecules, with a particular emphasis on targeting CD47 and CD20 to treat various forms of lymphoma.
Average Trading Volume: 3,544,634
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$5.37B
For a thorough assessment of 1541 stock, go to TipRanks’ Stock Analysis page.